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Abstract.
Background: The measurement of disease-relevant biomarkers has become a major component of clinical trial design,
but in the absence of rigorous clinical and analytical validation of detection methodology, interpretation of results may
be misleading. In Huntington’s disease (HD), measurement of the concentration of mutant huntingtin protein (mHTT) in
cerebrospinal fluid (CSF) of patients may serve as both a disease progression biomarker and a pharmacodynamic readout
for HTT-lowering therapeutic approaches. We recently published the quantification of mHTT levels in HD patient CSF by a
novel ultrasensitive immunoassay-based technology and here analytically validate it for use.
Objective: This work aims to analytically and clinically validate our ultrasensitive assay for mHTT measurement in human
HD CSF, for application as a pharmacodynamic biomarker of CNS mHTT lowering in clinical trials.
Methods: The single molecule counting (SMC) assay is an ultrasensitive bead-based immunoassay where upon specific
recognition, dye-labeled antibodies are excited by a confocal laser and emit fluorescent light as a readout. The detection
of mHTT by this technology was clinically validated following established Food and Drug Administration and European
Medicine Agency guidelines.
Results: The SMC assay was demonstrated to be accurate, precise, specific, and reproducible. While no matrix influence
was detected, a list of interfering substances was compiled as a guideline for proper collection and storage of patient CSF
samples. In addition, a set of recommendations on result interpretation is provided.
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Conclusions: This SMC assay is a robust and ultrasensitive method for the relative quantification of mHTT in human
CSF.
Keywords: Assay validation, biomarker, cerebrospinal fluid, huntingtin protein, Huntington’s disease, immunoassay, mutant
huntingtin, polyglutamine, ultrasensitive assay
INTRODUCTION
The availability of biomarkers can greatly facili-
tate the interpretation of clinical trial results, but the
use of poorly validated assays to detect them has
resulted in a profound lack of useful biomarkers.
The biomarker pipeline was recently described as
“plagued by problems” and “too prone to failures”
by Ioannidis and Bossuyt [1]. In the present work
we provide a rigorous analytical clinical validation
of an assay we previously demonstrated to be able
to detect mutant huntingtin (mHTT) in human cere-
brospinal fluid (CSF) of Huntington’s disease (HD)
mutation carriers [2].
HD is a neurodegenerative condition caused by
the expansion of a CAG nucleotide repeat domain in
the HTT gene [3]. This results in the expression of a
polyglutamine expanded huntingtin protein (mHTT)
that ultimately causes neuronal death [4]. This fact,
together with HD being a penetrant monogenic
disease, strengthens the concept of decreasing mHTT
levels as the most proximal therapeutic strategy for
disease modification [5]. To this aim, the quantifica-
tion of mHTT in CSF, an accessible central nervous
system (CNS) related body fluid, may be informa-
tive not only as a biomarker for patient stratification,
but also as a target engagement pharmacodynamic
measure for mHTT-lowering therapeutics, such as
RNAi modalities [6, 7]. We recently described a
novel single molecule counting (SMC) method capa-
ble of detecting and quantifying mHTT in human
and animal model CSF [2]; subsequently another
method using microbeads-based immunoprecipita-
tion followed by flow cytometry (IP-FCM) [8] was
reported. Both techniques are immunoassays based
on antibody pairs; in each method, one detects total
HTT and the other preferentially detects mHTT medi-
ated by the expanded polyglutamine recognition. The
polyglutamine directed antibody is MW1 [9] in both
the SMC and IP-FCM assays, whereas the HTT spe-
cific antibody 2B7 is used in the SMC assay, and
HDB4E10 is used in the IP-FCM assay. To date,
the extent of validation that has been carried out for
these assays has been focused on the demonstration
of selective and specific recognition of the mHTT
protein over the wild type protein (wtHTT) by using
recombinant protein standards.
The present work aims at providing a detailed ana-
lytical clinical validation of the SMC assay based
on the 2B7-MW1 antibody pair in order to provide
a strong data foundation for its use in future clin-
ical trials. To this end, the 2B7-MW1 assay was
preliminarily tested for its specificity for detection of
mHTT over wtHTT recombinant protein. Hereafter,
the Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) bioanalytical
method guidelines [10, 11] were applied to tech-
nically validate the 2B7-MW1 assay by SMC in
human CSF samples. This assay, enabled by the Sin-
gulex Erenna platform, is relative quantitative and
the mHTT amount present in biological samples is
calculated against a purified recombinant mHTT pro-
tein standard curve [2]. Our validation of the assay
comprised the evaluation of calibration curve perfor-
mance, accuracy, precision, stability, matrix effects,
selectivity, specificity, and reproducibility.
MATERIALS AND METHODS
Human CSF and blood samples
Human CSF and blood samples were collected
from healthy and HD patients, at University Col-
lege London (UCL) by Dr E. Wild and human
CSF samples were collected from healthy and HD
patients at the Centre for Molecular Medicine and
Therapeutics of Vancouver (BC, Canada) by Dr
B.R. Leavitt as previously described [2]. All work
involving human volunteers was performed in accor-
dance with the Declaration of Helsinki of 1975 and
approved by the Central London Research Ethics
Committee and the University of British Columbia
Clinical Research Ethics Board. All participants pro-
vided written informed consent.
In order to perform the assay, the samples and ref-
erence proteins were diluted in artificial CSF (aCSF):
PBS, 300 mM NaCl, 6 mM KCl, 2.8 mM CaCl2,
1.6 mM MgCl2.
Human blood, serum, and plasma with EDTA K2,
EDTA K3, Na-citrate, Na-Heparin and Na-EDTA
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were purchased from Seralab in order to test
the assay selectivity. Hemoglobin A quantification
was performed using a commercial ELISA (Bethyl
Laboratories) according to the manufacturer’s speci-
fication.
HTT silencing in human HD ﬁbroblasts
Three primary fibroblast cells, collected from an
HD, JHD, and a compound heterozygous HD patient,
having 45/23, 176/23, and 50/40 glutamines respec-
tively, were obtained from The Coriell Institute for
Medical Research, Camden, NJ, USA (cat. num.
GM09197, GM01085, GM04857). HTT silencing
was carried out using HTT-specific siRNA from
SIGMA (cat. num. SASI HS01 00241076) and Lipo-
fectamine 2000 (Invitrogen) as transfecting reagent.
Transfected cells were collected 48 h after treatment
and lysed. Lysis was done in PBS, 0.4% Triton-X
and Protease Inhibitor cocktail tablets (complete from
Roche).
Antibodies and recombinant proteins
The MW1 antibody was developed by the late
Dr. Paul Patterson [9]. 2B7 antibody generation and
characterization were as previously described [12].
The 2B7 antibody was conjugated to magnetic par-
ticles (MPs), to a final concentration of 25g/mg of
MPs, and the MW1 antibody was labeled, to a final
concentration of 1g/l, using the Erenna capture
and detection reagent labeling kits from Singulex-
Millipore, following the manufacturer’s instructions.
Conjugated/labeled antibodies were diluted in Assay
Buffer (from Singulex-Millipore), prior to perform-
ing the assay, to 1:400 and 1:1000 respectively.
Purified recombinant proteins were obtained from
CHDI Foundation and produced as previously pub-
lished. The large fragment amino terminal human
HTT proteins HTT (1-573) Q23, HTT (1-573) Q45,
and HTT (1-573) Q73 were produced according to
Macdonald et al. [13], and the full length human HTT
proteins HTT (1-3144) Q17 and HTT (1-3144) Q46
were produced according to Huang et al. [14].
Immunoassay
The immunoassay was performed as previously
described [2]. Briefly, the assay starts with a capture
step, where the 2B7 conjugated-MPs are incubated
with samples for 1 h, in an Axygen polypropylene
V-bottom 96 well plate, previously coated with a
solution of 1X Erenna System Buffer (from Singulex-
Millipore) 750 mM NaCl, 6% BSA, 0.8% Triton-X
and protease inhibitor cocktail (Complete tablets
from Roche). Washes were performed on a magnetic
rack, using an Elx washer (from Biotek), in 1X Erenna
Wash Buffer (from Singulex-Millipore). Afterwards
MPs were incubated with MW1 detection antibody
for 1 h. Washes were performed again on a magnetic
rack, in an Elx washer, in 1X Erenna Wash Buffer.
The MPs were then transferred into a new Axygen 96
well plate to eliminate nonspecific binding to the plas-
tic. After buffer aspiration the elution buffer (acidic
glycine solution, 0.1 M, pH 2.7) was added to the plate
for 5 min of incubation under shaking. The eluted
detection antibody was transferred to a Nunc 384-
well analysis plate and neutralized with neutralization
buffer (Tris, 1 M, pH 9). The plate was spun down,
sealed and subsequently analyzed with the Erenna
Immunoassay System (Singulex-Millipore).
Data analysis
Data analysis was performed using GraphPad
Prism software in order to obtain standard curve
fitting and back-calculations on fitting models. The
standard curve was obtained without associating any
weight to each standard concentration.
RESULTS
Assay technology, antibodies, and detected
signals
Singulex Erenna technology provides high sensi-
tivity with a broad dynamic range [15] in a 384-well
plate format. The signal detected is a train of events
generated when dye-labeled molecules are excited
by the confocal laser of the instrument and emit fluo-
rescent light. The instrument measures three outputs
based on photon detection. The output best suited
to the generation of dilution curves described by
the standard protein is event photons (EP), which is
the average photon count in all detected events. To
perform the immunoassay, two anti-HTT antibod-
ies were used. The 2B7 antibody binds to the N17
region of HTT [12] and was conjugated to magnetic
particles for use as the capture antibody. The MW1
antibody recognizes the polyglutamine expansion of
mHTT [9] and was labeled with a fluorophore and
used as the detection antibody. Both antibodies are
well-established in the detection of mHTT by ELISA
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or time-resolved Fo¨rster resonance energy transfer
(TR-FRET) in biological samples where the mHTT
protein is relatively abundant, such as cellular lysates
or tissue homogenates [12, 13, 16].
Calibration curve performance
Calibration standards were prepared by spiking
known amounts of purified human recombinant
HTT proteins in aCSF, a CSF surrogate matrix that
matches the physiological electrolyte concentrations
of human CSF. Five forms of human recombinant
HTT protein were tested: three large fragment pro-
teins comprising the 1-573 N-terminal amino acids
(N573) and bearing polyglutamine expansions of 23,
45 and 73 glutamines in Exon 1; and two full length
proteins comprising the 1-3144 amino acids (FL) pro-
teins with 17 and 46 glutamines in Exon 1. Signals
obtained by serially diluting the N573 fragments and
FL proteins, starting from 4 pM and 25 pM respec-
tively, demonstrated the specificity of the assay in
detecting the mutant forms of HTT and its polyglu-
tamine dependency. In fact, the mHTT forms (N573
Q45, Q73 and FL Q73) were each well-detected in the
assayed range of concentrations, with detection per-
formance improving with polyglutamine length (i.e.,
N573 Q73 >N573 Q45). On the contrary, the detec-
tion of wild-type HTT forms (N573 Q23 and FL Q17)
is ineffective or just above the limit of detection (LoD)
at the highest tested concentrations (Fig. 1A).
The calibration curve performance was carried out
by using either FL or N573 HTT proteins bearing
pathological polyglutamine expansions of similar
length (Q46 and Q45, respectively). The dynamic
range is defined as lying between the lower and upper
limits of quantification (LLoQ and ULoQ): the lowest
and highest points of the curve for which the per-
centage relative error (systematic error or bias from
nominal value – % RE) and the random error (impre-
cision or percentage coefficient of variation – % CV)
are ≤25% [11, 17]. The determined LLoQ and ULoQ
were 6.5 and 8000 fM for the large fragment, and 16.5
and 8000 fM for the full-length protein (Fig. 1B).
It has to be noted that, the same concentration of
the full length and the large fragment protein, bear-
ing almost the same polyglutamine stretch (Q46 and
Q45, respectively), were detected with one log differ-
ence in intensity with the large fragment producing
a higher signal than the full length (Fig. 1B). This
observation suggests that HTT detection is not only
influenced by the length of polyglutamine expansion,
but also by the size of protein.
In order to identify a proper fitting function, data
points relative to the N573 Q45 protein were fit-
ted with linear regression, four-parameter logistic
(4PL) and five-parameter logistic (5PL) models [18]
(Fig. 2A-C). The values calculated by the three fitting
models were compared with the ones measured by the
assay determining the % RE and the % CV. The sum
of the % RE and the % CV is defined as the percentage
total error (% TE). The model that best fits the protein
detection is the one where the majority of the dilution
points (at least four of six points) do not exceed the
30% of TE; this rule is known as the 4-6-30% rule
Fig. 1. Calibration curve performance and definition. Detection of human recombinant (hr) full length (with 17 and 46 glutamines in the
polyglutamine stretch) and N573 (with 23, 45, and 73 glutamines in the polyglutamine stretch) HTT protein by the 2B7-MW1 SMC assay.
A) Polyglutamine and protein length-dependency in HTT detection were demonstrated analyzing the five proteins. B) A longer series of
protein dilutions was analyzed for both the full length Q46 and the N573 Q45 in order to define the LLoQ and ULoQ of the assay. These two
values were calculated as the lowest (above the LoD) and the highest points of the standard curve for which % CV and % RE are <25 [19].
They are 6.5 and 10000 fM for the large fragment and 16.5 and 10000 fM for the full length protein. The X and Y axes have logarithmic
scales and the curves were fitted with a parameter logistic (5PL) model. Each point is the mean of 3 replicates. Bars represent standard
deviation. LoD was calculated as the mean of the blank EP values plus three times the standard deviation.
V. Fodale et al. / Ultrasensitive Mutant HTT Detection in Human CSF 353
Fig. 2. Standard curve fitting model evaluation. EP values obtained from the 2B7-MW1 SMC analysis of serial dilutions of N573 Q45 HTT
protein were fitted using (A) linear regression, (B) four-parameter logistic (4PL), and (C) 5PL models. Each point is the mean of 3 replicates.
Bars represent standard deviation. (D) % TE and % RE were evaluated for each dilution point for the three fitting models. The 4PL and
5PL models achieved less than 30% error for points within the quantification range of the assay, as required by the EMA assay validation
guideline. For the 5PL model, all assayed dilutions including the one below the LLoQ, showed error <30%.
originally described by DeSilva et al. and adopted by
the EMA assay validation guidelines [11, 18, 19]. In
our study, the linear regression model was demon-
strated to be inadequate since using this model, 50%
of the analyzed points show a % TE >30 (Fig. 2A, D).
The 4PL model instead was shown to be compliant
with the above-mentioned rule for the dilution points
within the quantification range of the assay (Fig. 2B,
D); the 5PL model was compliant with the rule for all
the dilution points (including those under the LLoQ)
and was thus used in the following validation steps
(Fig. 2C, D).
Accuracy and precision of the standard curve
The accuracy and precision of the standard
curve for detection of mHTT were investigated by
within-run (intrabatch) and between-run (interbatch)
assessment. Within-run evaluation was carried out
by testing three technical replicates of each stan-
dard concentration in a single run, while between-run
evaluation was performed by at least six indepen-
dent standard curves assayed on different days. The
obtained results show that % RE (Table 1A) and %
CV (Table 1B) were less than 20% in all the batch
runs for mHTT concentrations between the LLoQ
and ULoQ. These results are compliant with the EMA
guidelines for bioassay validation [11]. For CV and
RE calculation, intrabatch precision was estimated by
the pooled intrabatch standard deviation of the mean
of the calculated concentrations, while interbatch pre-
cision (total random error) was estimated by analysis
of variance (ANOVA). Statistical methods and for-
mulas used were as described in detail by DeSilva
et al. [18].
Speciﬁcity for human endogenous HTT protein
We initially proceeded to investigate whether the
assay is suitable for specifically detecting endoge-
nous mHTT protein by conducting an HTT detection
specificity study in cells. To this aim we used pri-
mary fibroblasts from one juvenile HD (JHD) and two
adult-onset HD patients expressing mHTT containing
176/23, 45/23, 50/40 glutamines, respectively. These
cells were transfected with an HTT-specific siRNA
and a scrambled control siRNA, then lysed and col-
lected after 48 h. HTT silencing was achieved to a
level between 50–60% of the scrambled transfected
cells, as determined by quantitative RT-PCR mea-
suring HTT mRNA (data not shown). When mHTT
protein levels were quantified using the 2B7-MW1
SMC assay on silenced and control cells a decrease
of the target protein, similar to the observed mRNA
decrease, was detected. This provides a preliminary
demonstration of the assay’s validity in complex
matrices (Fig. 3).
Analyte stability
To demonstrate that the 2B7-MW1 SMC assay is
suitable for the study of biological samples, accu-
racy and precision have to be assessed on validation
samples (VS). VS are real biological samples pre-
pared once and then tested, with the same standard
operating procedure as all investigational samples,
in every single analyte quantification study to val-
idate the performance of the assay. At least five
VS should be used to assess accuracy, precision
and the total error of the method: an anticipated
ULoQ control (VS1); a high control (VS2); a mid-
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Table 1
Accuracy and precision. Accuracy and precision of the 2B7-MW1 SMC mHTT (N573 Q45) detection assay were investigated within-run
(intrabatch), by testing three technical replicates of each standard concentration, and between-run (interbatch), by testing six independent
standard curves. % RE (A) and % CV (B) measured for each standard concentration in each run are reported. Both values were demonstrated
to be less than 20% for all the concentrations between LLoQ and ULoQ for each run. Intrabatch and Interbatch % CV and % RE were
estimated using the statistical methods described by DeSilva et al. [18]. Both interbatch and intrabatch precision and accuracy in %CV and
%RE calculation were demonstrated to be <20%
A. Percent Relative Errors (%RE) of Back-Calculated Standard Concentration
Nominal Concentration (fM)
Batch Run 4000 1600 640 256 102 41 16
1 –1.15 2.01 5.07 –10.50 7.20 4.41 9.31
2 1.85 –3.63 0.61 –1.89 9.97 –6.72 1.16
3 –0.47 4.40 2.87 –7.77 4.25 4.66 –6.32
4 2.80 –4.29 10.67 –11.82 10.09 1.11 –3.66
5 7.58 –10.10 4.35 –0.04 7.44 –6.58 1.83
6 0.72 –4.50 8.86 –7.64 4.21 1.74 –1.93
Intrabatch (within-run) Statistics (Pooled):
1.89 –2.39 5.09 –6.61 7.20 –0.23 –0.08
Interbatch (between-run) Statistics (ANOVA):
1.89 –2.68 5.40 –6.61 7.20 –0.23 0.06
ULOQ LLOQ
B. Percent Coefﬁcient of Variation (%CV) of Back-Calculated Standard Concentration
Nominal Concentration (fM)
Batch Run 4000 1600 640 256 102 41 16
1 4.80 8.22 11.26 14.32 9.89 13.18 29.71
2 3.59 6.53 17.70 12.72 8.54 10.97 5.27
3 15.98 16.42 16.01 12.97 5.24 9.10 2.58
4 18.42 1.83 2.22 11.65 9.65 4.39 5.08
5 9.61 14.89 10.41 13.05 7.53 16.06 8.81
6 8.81 3.38 16.54 16.67 8.40 18.17 3.61
Intrabatch (within-run) Statistics (Pooled):
11.55 11.43 14.02 13.66 8.35 12.81 11.92
Interbatch (between-run) Statistics (ANOVA):
12.96 12.31 15.91 15.05 9.29 13.86 13.28
ULOQ LLOQ
control (VS3); a control that is more than three times
the LLoQ (VS4); and an anticipated LLoQ control
(VS5) [11]. These VS were prepared by pooling CSF
from healthy and HD donors and, finally, spiking
recombinant mHTT protein in order to obtain the
five desired mHTT concentrations as presented in
Fig. 4A.
VS were also evaluated for their stability after
two freeze-thaw cycles by measuring their variation
(% RE) from the initial mHTT concentration. The
obtained recovery rate was less than 80% after the
first freeze/thaw cycle and decreased even more than
50% after the second cycle (Fig. 4B). One possible
determinant of this loss may be the propensity of
mHTT to form aggregates by hydrophobic interac-
tions [20]. For this reason, the addition of a detergent
was evaluated to prevent mHTT aggregation. Indeed,
1% Tween-20 stabilized the concentration of mHTT
in VS after two freeze-thaw cycles to a % RE between
80 and 120% (Fig. 4C). As a consequence, the addi-
tion of 1% Tween-20 is recommended to preserve
the integrity of mHTT by preventing possible ex vivo
precipitation, oligomerization, or aggregation.
Parallelism, dilution linearity, and spike recovery
The parallelism test is used to demonstrate that the
endogenous analyte in its biological matrix behaves
in a similar immunochemical manner to the standard
protein in the same matrix or in a substituted one
[19]. In the present work, parallelism was assessed
between the calibration standard curve and serially-
diluted HD CSF samples in order to exclude possible
off-target affinities for other matrix resident analytes
and to validate the use of aCSF as substituted matrix
for the standard curve [19]. A preliminary evaluation
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of parallelism was made using the similarity between
the curve shape of the CSF dilutions, where at least
three points fell within the quantification range, and
the standard mHTT curve (Fig. 5A). Parallelism
was assessed verifying that the variation (% RE)
between back-calculated sample concentrations in a
Fig. 3. Specificity for human endogenous HTT protein. The 2B7-
MW1 SMC assay specificity was demonstrated by analyzing HTT-
silenced fibroblasts derived from one JHD and two adult-onset HD
subjects. Cells were transfected with an HTT-specific siRNA and a
scrambled control. The decrease in mHTT protein levels, as back-
calculated on the N573 Q45 standard protein, detected in siRNA
treated cell lines, with respect to the scramble treated ones, was
found to be coherent with the decrease in HTT mRNA (data not
shown).
dilution series does not exceed 30% [11]. Results are
represented in Fig. 5B, where the calculated concen-
trations (observed concentration × dilution factor)
were divided by the mean of the concentrations and
plotted against the inverse of the dilution factor [19].
The calculated ratio was not affected by sample dilu-
tion for the four samples which were detected within
the quantification range of the assay. Back-calculated
mHTT levels were found to not exceed 20% RE in
those samples, thus validating the dilution linearity of
the assay and consequently its parallelism. Further-
more, the two CSF samples from premanifest HD
patients showed a % RE within the 30%, even if they
were below the LLoQ, demonstrating that a matrix
effect is not observed in real CSF samples using the
2B7-MW1 SMC assay.
mHTT spike recovery was carried out to evaluate
the influence of the CSF matrix in mHTT detection
by the assay [19]. Recombinant mHTT protein N573
Q45 was spiked and diluted in aCSF and in five real
CSFs collected from HD patients. The spike recov-
ery rate percentage was calculated by comparing the
assay-determined mHTT amount to a nominal one,
after subtracting the sample basal mHTT levels [19,
21]. All mHTT concentrations spiked in the six matri-
ces were recovered within the acceptable range of
80–120 % (Fig. 6).
Fig. 4. Stability evaluation. Signals obtained from five validation samples (VS) with mHTT levels distributed across the quantification range
and their stability. (A) N573 Q45 standard dilutions (black dots) are interpolated with a 5PL model. VS1 anticipates ULoQ, VS2 is a high
control, VS3 is a mid-control, VS4 is less than three times the LLOQ and VS5 anticipates LLoQ [11]. Each point is the average of 3 replicates.
Bars represent standard deviation. (B, C) Variations in the detection of mHTT in VS detected by the 2B7-MW1 SMC assay on fresh samples
after storage at –80◦C (first cycle of freeze/thaw), or after 6 h at room temperature (RT), or after the second cycle of freeze/thaw, (B) without
preservative or (C) with the addition of 1% Tween. The addition of 1% Tween greatly improved the stability of HTT in all tested conditions
(the accuracy % RE remained between 80 and 120 %).
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Fig. 5. Parallelism evaluation. Six CSF samples were used: four CSF from advanced HD patients and two CSF from pre-manifest HD
patients. (A) N573 Q45 standard dilutions (black dots) are interpolated with a 5PL model and shown in each plot together with the signal
obtained from 2B7-MW1 SMC analysis of the CSF. X and Y axes have logarithmic scales and the curves were fitted with a 5PL model. Each
point is the average of 3 replicates. Bars represent standard deviation. (B) Parallelism was demonstrated by dilution linearity. Calculated
mHTT concentrations (observed concentration × dilution factor) were divided by the mean of the concentrations and plotted against the
inverse of the dilution factor [19]. The %RE among the dilution points was <20% for all the samples detected over the LLoQ and <30% for
the two samples detected under the LLoQ.
Fig. 6. Spike recovery evaluation. Seven dilutions of the N573 Q45 recombinant protein were spiked in aCSF and in five CSF samples
collected from HD patients. (A) The obtained curves were fitted with a 5PL model. The X and Y axes have logarithmic scales. Each point
is the mean of 3 replicates. Bars represent standard deviations. (B) The spike recovery rate of five HTT dilutions was between 80 and 120
% of the nominal concentration in all the tested matrices.
Selectivity
The selectivity of the 2B7-MW1 SMC assay was
evaluated in order to demonstrate the suitability of
the assay to detect mHTT unequivocally even in the
presence of additives and/or contaminants in the tar-
get matrix [10, 19]. The former deals with chemicals
added to CSF samples to preserve them; the latter
is dependent on accidental CSF contamination dur-
ing sampling by other tissues such as blood. Both
the FDA and the EMA guidelines for bioanalyti-
cal method validation suggest performing selectivity
tests in real biological matrices; nonetheless the vol-
ume of human CSF required to complete the study
with all the selected contaminants was incompatible
with the availability of HD CSF. To overcome this
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Fig. 7. Selectivity evaluation. The selectivity of the 2B7-MW1 SMC assay was assessed against multiple concentrations of potential
interfering substances. Different concentrations of eight components were spiked into artificial CSF: (A) plasma with EDTA K2, EDTA
K3, sodium citrate, sodium heparin and sodium EDTA, serum and (B) blood collected from six HD subjects and one healthy control. EP
signals are reported with respect to the % spike in aCSF in A, or against human hemoglobin concentration in B. Each point is the mean of 3
replicates. Bars represent standard deviations. Numeric results are summarized in Table 2.
limitation, aCSF was used instead of HD CSF. Our
findings for parallelism, dilution linearity and spike
recovery, described above, demonstrate the suitabil-
ity of aCSF as a matrix surrogate in the determination
of the assay’s selectivity for mHTT.
Selectivity was assessed by analyzing multiple
concentrations of the following potential interfering
substances: human plasma pooled from healthy donor
with EDTA K2, EDTA K3, sodium citrate, sodium
heparin and sodium EDTA (which are commonly
used as anti-coagulants and sample preservatives),
serum and whole blood (which can be present in CSF
due to sampling contamination).
The obtained results demonstrated that up to 10%
plasma with sodium heparin or serum did not affect
the assay signal. In contrast, plasma with EDTA
K2, EDTA K3, sodium citrate, and sodium EDTA
concentrations higher than 2, 0.4, 0.3, and 0.08%
respectively resulted in signals higher that the LoD
(Fig. 7A), suggesting that they should be avoided
as CSF preservatives. A summary of all the additive
thresholds is reported in Table 2.
Table 2
Summary of selectivity test results. Contaminant interference in
the detection of mHTT and the corresponding threshold concen-
trations for each tested substance
Presevative/Contaminant mHTT detection Acceptance
interference criteria
Plasma w EDTA K2 Yes ≤2%
Plasma w EDTA K3 Yes ≤0.40%
Plasma w Na-citrate Yes ≤0.30%
Plasma w Na-Heparin No up to 10%
Plasma w Na-EDTA Yes ≤0.08%
Serum No Up to 10%
Hemoglobin Yes ≤2g/ml
While CSF is normally centrifuged after sampling
in order to remove blood cells, soluble components of
blood and the contents of already-hemolyzed blood
cells cannot be removed. The presence of hemolyzed
blood was found to impact the assay process by
causing the magnetic particles to clump. In addi-
tion to this general hemolyzed blood interference,
blood contamination may alter mHTT levels in CSF
by specifically adding mHTT to the CSF. To assess
this possibility, blood from six HD patients was seri-
ally diluted in aCSF, starting from a concentration
of 0.15%, and analyzed by the 2B7-MW1 Singulex
assay. Hemoglobin (HbA) levels for all blood dilu-
tions were measured and employed as an independent
means of quantifying blood contamination that could
then be used to establish a hemoglobin threshold
below which contamination of CSF by mHTT from
blood is expected to be negligible.
The correlation between mHTT and hemoglobin
levels is reported in Fig. 7B. An appreciable signal
was detected at blood spikes greater than 0.002%,
corresponding to 2g/mL of hemoglobin which, as
a consequence, was fixed as threshold for mHTT
quantification in HD CSF.
All the thresholds of the tested contaminants,
which may interfere with mHTT detection by the
2B7-MW1 SMC assay, are summarized in Table 2.
Reproducibility
The reproducibility of an assay is determined by
the incurred sample reanalysis (ISR), which is the
reanalysis of a portion of subject samples to deter-
mine whether the original results are reproducible
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[10, 11]. The ISR was carried out on 24 HD CSF sam-
ples (i.e., 10% of a putative 240-participant study)
analyzed in triplicate. Three healthy CSF samples
were included as negative controls. The time between
the first and the second analysis was set to one week,
whereas five weeks elapsed between the first and
the third analysis. After collection, samples were
aliquoted in single-use vials to avoid multiple freeze-
thaw cycles among the different runs. The three
control sample results were lower than the LLoQ,
confirming the assay specificity. One HD CSF sample
result was lower than the LLoQ; thus it was excluded
from the ISR study. Hemoglobin levels in the remain-
ing samples were below the 2g/mL threshold with
the exception of one sample, which was excluded
from the ISR study (see Table 3). The RE for each
run was calculated with respect to the average mHTT
concentration. 77.3% of tested samples showed a RE
within 30% (Table 3), which is compliant with the
assay validation guidelines for large molecules, being
greater than the two-thirds (67%) of the incurred sam-
ples. [10, 11].
DISCUSSION
One of the more promising therapeutic approaches
to mitigate or modify the course of HD is based
on various techniques to lower the expression of
mHTT protein. In order to enable such therapeutic
approaches, biomarkers of HTT lowering must be
developed to demonstrate that delivery of a HTT low-
ering agent does indeed lower the amount of HTT
protein in the brain of an HD patient. Since the
brain cannot be non-invasively used for a pharmaco-
dynamic examination, the analysis of brain-derived
proteins enriched in patient CSF can provide a “win-
dow into the brain” [6, 22, 23] and represents the most
accessible opportunity to biochemically sample the
CNS milieu.
The aim of the present work was to clinically val-
idate the approach proposed by Wild and Boggio
et al. that is based on the use of the 2B7-MW1 SMC
assay as a biomarker for HTT lowering therapeu-
tic approaches. The validation process was carried
out following the recommendations of both the FDA
and EMA [10, 11]. One partial limitation complicat-
ing this validation study was the limited availability
of HD patient CSF. Nonetheless, the parallelism,
dilution linearity, and spike recovery studies demon-
strated that patient CSF matrix can be substituted by
aCSF and that the recombinant mHTT protein used to
perform the reference standard is detected in a similar
biochemical manner to endogenous mHTT protein.
The assay was demonstrated to be specific for mHTT
with a lower limit of detection of 6.5 fM for the N573
Q45 and 16.5 fM for the FL Q46. It has to be noted
that the assay better detects the shorter form of mutant
HTT (N573) than the full length one (FL) even though
the two were almost identical in terms of polyglu-
tamine expansion. This fact may be relevant when
interpreting results, as there are reports showing that
endogenous mHTT is present in various truncated
forms in cells resulting from proteolytic cleavage as
well as proteosomal degradation [24–26].
CSF matrix composition was demonstrated not to
interfere with the assay throughout a wide range of
dilutions. Still, we recommend the addition of 1%
Tween-20 to CSF, at the time of sampling or after the
first thawing, to retain the integrity of the biosample
by avoiding possible loss of mHTT due to protein
precipitation, oligomerization, or aggregation. When
various additives were tested for their interference,
plasma with EDTA K2, EDTA K3, Na-citrate, or NA-
EDTA were found to impact on mHTT quantification;
thus their use should be avoided. With regard to
contaminant influence, hemolyzed blood was demon-
strated to be a potential major issue when hemoglobin
exceeds 2g/ml due to both matrix effect and serum
mHTT contamination: thus we recommend that CSF
samples containing hemoglobin levels above this
threshold be avoided. Finally, the assay was demon-
strated to be reliable as mHTT levels in 77.3% of a
22 pre-/early manifest group were consistently quan-
tified over three independent runs.
Despite our demonstration that the 2B7-MW1
SMC assay is accurate and precise, there are some
recommendations that should be taken into account
when interpreting data produced by the present pro-
cedure. First, it has to be considered that the output of
mHTT quantification is dependent, to some extent, on
two important factors: the poly-glutamine expansion
size and the protein size. Therefore, in absence of a set
of standard recombinant mHTT proteins with every
single possible combination of polyglutamine expan-
sions and protein fragments, the calculated mHTT
concentration must be considered as a best estimate
rather than an absolute value; as a consequence the
assay can be defined as relatively quantitative [17]. A
consequence is that the most meaningful results will
likely be obtained in paired analyses where a single
subject is monitored over time – such as within the
setting of a clinical trial. A further consideration is
the choice between N573 and FL standard mHTT.
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Table 3
Reproducibility evaluation. Reproducibility of the 2B7-MW1 SMC mHTT detection assay was successfully investigated by testing 22 CSF samples, collected from HD patients, in three independent
runs. The mean of mHTT concentrations obtained in each of the three runs is reported, together with CV % and RE %. The RE % was calculated with respect to the average of concentration
obtained from the three runs (indicated as AVE). Asterisks indicate samples which failed to meet one of the following criteria: HbA <2g/ml, CV <30% or RE <30%
Sample ID Hemoglobin Average HTT fM AVE SD CV% Note Recovery % w.r.t. AVE RE %
g/ml run #1 run #2 run #3 run #1 run #2 run #3 run #1 run #2 run #3
HD 1 0.47 109.09 147.59 90.22 115.63 29.24 25.29 94.35 127.63 78.02 –5.65 27.63 –21.98
HD 2 2.95∗ 98.03 340.09 75.36 171.16 146.74 85.73∗ Hb >2 g/ml excluded from reproducibility analysis
HD 3 0.22 61.02 97.73 63.21 73.98 20.59 27.83 82.48 132.09 85.43 –17.52 32.09∗ –14.57
HD 4 0.33 11.10 14.80 10.63 12.18 2.29 18.76 91.18 121.55 87.27 –8.82 21.55 –12.73
HD 5 0.14 75.88 86.95 78.55 80.46 5.78 7.19 94.30 108.07 97.63 –5.70 8.07 –2.37
HD 6 0.23 116.81 156.66 73.77 115.75 41.46 35.82∗ 100.92 135.35 63.73 0.92 35.35∗ –36.27∗
HD 7 0.34 35.55 48.13 43.15 42.28 6.34 14.99 84.08 113.85 102.07 –15.92 13.85 2.07
HD 8 <LoD 28.55 32.15 35.42 32.04 3.44 10.73 89.10 100.35 110.55 –10.90 0.35 10.55
HD 9 0.09 41.35 43.25 42.50 42.37 0.96 2.26 97.60 102.09 100.30 –2.40 2.09 0.30
HD 10 0.43 32.63 35.75 22.70 30.36 6.81 22.44 107.48 117.74 74.78 7.48 17.74 –25.22
HD 11 0.15 15.23 20.00 233.15 89.46 124.46 139.12∗ 17.03 22.36 260.62 –82.97∗ –77.64∗ 160.62∗
HD 12 0.40 73.27 96.72 86.82 85.60 11.77 13.75 85.59 112.98 101.42 –14.41 12.98 1.42
HD 13 0.09 59.93 69.33 58.37 62.54 5.93 9.48 95.82 110.85 93.33 –4.18 10.85 –6.67
HD 14 0.33 427.62 365.50 220.00 337.71 106.57 31.56∗ 126.63 108.23 65.15 26.63 8.23 –34.85∗
HD 15 0.34 58.15 75.93 64.50 66.19 9.01 13.61 87.85 114.71 97.44 –12.15 14.71 –2.56
HD 16 0.06 22.20 20.53 20.00 20.91 1.15 5.49 106.17 98.19 95.64 6.17 –1.81 –4.36
HD 17 0.18 14.55 20.37 26.57 20.50 6.01 29.32 71.00 99.37 129.63 –29.00 –0.63 29.63
HD 18 0.04 238.00 109.52 57.64 135.05 92.85 68.75∗ 176.22 81.10 42.68 76.22∗ –18.90 –57.32∗
HD 19 0.10 121.61 171.77 116.60 136.66 30.51 22.33 88.99 125.69 85.32 –11.01 25.69 –14.68
HD 20 0.07 3.50 1.06 1.23 1.93 1.36 70.43∗ <LLoQ excluded from reproducibility analysis
HD 21 0.40 82.20 102.18 58.50 80.96 21.87 27.01 101.53 126.22 72.25 1.53 26.22 –27.75
HD 22 <LoD 48.13 56.75 59.30 54.73 5.85 10.70 87.95 103.70 108.35 –12.05 3.70 8.35
HD 23 <LoD 149.29 186.44 149.90 161.88 21.28 13.14 92.23 115.18 92.60 –7.77 15.18 –7.40
HD 24 <LoD 51.57 76.65 64.65 64.29 12.55 19.51 80.21 119.23 100.56 –19.79 19.23 0.56
Healthy 1 <LoD 3.08 4.62 3.25 3.65 0.84 23.12 <LLoQ excluded from reproducibility analysis
Healthy 2 <LoD 3.05 4.79 2.09 3.31 1.37 41.34∗ <LLoQ excluded from reproducibility analysis
Healthy 3 <LoD 3.30 6.02 1.13 3.48 2.45 70.20∗ <LLoQ excluded from reproducibility analysis
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Because the performance of these two standards is
different, mHTT levels can be compared only when
a single standard is used across different runs. More-
over, in consideration of the propensity of mHTT to
aggregate, the quality of the standard proteins must
be periodically controlled by independent methods
such as native PAGE.
The present work demonstrated that the presence
of hemolyzed blood is highly detrimental to the
assay performance. When the contamination is evi-
dent it impairs the assay performance, while at minor
contamination (>2g/ml of hemoglobin) errors in
mHTT determination were observed. Therefore, a
third recommendation would be to always quantify
hemoglobin levels in the CSF prior to running the
mHTT quantification in order to exclude contami-
nated samples from the study.
Finally, to better interpret the mHTT concentration
levels, ancillary biomarkers such as the total pro-
tein amount in the CSF should be used that provide
an additional characterization of the testing matrix
[27, 28].
In conclusion, the present work, guided by FDA
and EMA principles, demonstrates that the 2B7-
MW1 assay is a valid, robust, reproducible, and
ultrasensitive method for the relative quantification
of mHTT in human CSF.
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